Hims & Hers Health, Inc. (HIMS) Announced Q4 2025 Earnings on February 23, 2026, Reporting "Revenue in the fourth quarter was $618 million".

Hims & Hers Health, Inc. reported fourth quarter 2025 revenue of $618 million, representing a year-over-year growth rate of 28%. For the 2025 fiscal year, the company generated revenue of $2.35 billion, a 59% year-over-year growth rate. Fourth quarter adjusted EBITDA was $66 million, reflecting an 11% margin, while full year 2025 adjusted EBITDA increased nearly 80% year-over-year to $318 million. The company generated over $57 million in free cash flow in 2025 and ended the year with $929 million of cash, short-term and long-term investments on its balance sheet.

Throughout 2025, subscribers on the platform grew to over 2.5 million, with approximately 65% utilizing a personalized treatment. Management highlighted the company's evolution toward "proactive and preventative care" by bringing new offerings to market. Within a 90-day span, Hims & Hers launched a new Labs offering as well as hormone therapies supporting low testosterone, menopause, and perimenopause. The company also expanded its international presence through the acquisitions of ZAVA and Livewell, serving consumers in markets including the U.K., Germany, and Canada.

Looking ahead, management announced an agreement to acquire Eucalyptus, a global health innovator, for up to $1.15 billion in total consideration to expand into Australia and Japan. For the first quarter of 2026, Hims & Hers is anticipating revenue in the range of $600 million to $625 million and adjusted EBITDA between $35 million to $55 million. For the full year 2026, the company expects revenue between $2.7 billion to $2.9 billion and adjusted EBITDA between $300 million and $375 million, which excludes the pending Eucalyptus transaction.